1. Home
  2. AKBA vs BRT Comparison

AKBA vs BRT Comparison

Compare AKBA & BRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo BRT Apartments Corp. (MD)

BRT

BRT Apartments Corp. (MD)

HOLD

Current Price

$14.88

Market Cap

278.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
BRT
Founded
2007
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
278.2M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
AKBA
BRT
Price
$1.22
$14.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$4.67
$19.75
AVG Volume (30 Days)
4.1M
43.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
7.03%
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$97,028,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
$5.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.46
52 Week Low
$0.82
$13.18
52 Week High
$3.81
$16.69

Technical Indicators

Market Signals
Indicator
AKBA
BRT
Relative Strength Index (RSI) 46.66 50.38
Support Level $1.16 $14.27
Resistance Level $1.52 $15.04
Average True Range (ATR) 0.07 0.45
MACD -0.02 -0.02
Stochastic Oscillator 7.59 55.91

Price Performance

Historical Comparison
AKBA
BRT

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About BRT BRT Apartments Corp. (MD)

BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.

Share on Social Networks: